Search
Menu
Home
HTB
2012
October
01
1 October 2012
Contents
Editorial
Volume 13 Number 9/10 September/October 2012
In memory
Jerome Horwitz dies at 93
Supplements
AIDS 2012: a non-technical review of the 19th IAS Conference
Conference reports
52nd International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 9-12 September 2012, San Francisco
Study summaries from ICAAC 2012
Antiviral activity in vitro with S/GSK1265744
Efavirenz interaction studies with TB compounds bedaquiline and delamanid
19th IAS World AIDS Conference, 22–25 July 2012, Washington
HPTN-052: clinical advantages from earlier treatment
Hormonal contraception and the risk of HIV acquisition
Towards an HIV cure: Early developments reported at IAS, part 2
Online video interviews between researchers and activists
Antiretrovirals
FDA approves Quad in US: price may prohibit UK access
Merck acquires CMX157 and EFdA and starts phase 2 study for new NNRTI
Roche to discontinue production of nelfinavir and saquinavir 200 mg hard capsules
Treatment access
FDA approval of generic ARVs
Free HIV treatment in the UK for all, irrespective of residency status
Robin Hood Tax begins in France
Novartis case enters Indian Supreme court
India: Bayer stay order against compulsory licence denied
PK and drug interactions
Ritonavir significantly increases exposure to colchicine (gout)
Ritonavir interaction with quinine is clinically insignificant but may warrant caution
Case report: fluticasone, fluconazole and ritonavir interactions
Guidelines
UK Standards for HIV Care online for comment (2012)
HIV in England to remain as nationally commissioned specialist service
US guidelines include Stribild (Quad) as alternative rather than preferred option for treatment naive adults (2012)
IAS USA update adult ARV treatment guidelines (2012)
Side effects
Increased incidence of ischemic stroke amongst HIV positive cohort
TB coinfection
Costs for rapid TB test reduced by 40%
Important advances in TB drug development
Virology
Discord controllers: characterising a new viremic controller phenotype
PDFs
Volume 13 Number 9/10 September/October 2012 PDF
HTB RSS
Early access
HIV organisations support trans and non-binary communities against the unworkable EHRC guidelines
30 June 2025
Long-acting injectable PrEP approved in the US: priced at $28,000 a year
28 June 2025
Clinical studies of two once-weekly pipeline compounds put on hold
27 June 2025
UK HIV care for transgender and non-binary people: comment on unworkable EHRC guidelines by 30 June
26 June 2025
All early access reports
Current issues
June 2025
May 2025
April 2025
Back issues
Special report
UK HIV care for transgender and non-binary people: comment on unworkable EHRC guidelines by 30 June
26 June 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate